CoChat

Isomerization of a Single Aspartyl Residue of Anti-Epidermal Growth Factor Receptor Immunoglobulin γ2 Antibody Highlights the Role Avidity Plays in Antibody Activity

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

A new isoform of the light chain of a fully human monoclonal immunoglobulin gamma2 (IgG2) antibody panitumumab against human epidermal growth factor receptor (EGFR) was generated by in vitro aging. The isoform was attributed to the isomerization of aspartate 92 located between phenylalanine 91 and histidine 93 residues in the antigen-binding region. The isomerization rate increased with increased temperature and decreased pH. A size-exclusion chromatography binding assay was used to show that one antibody molecule was able to bind two soluble extracellular EGFR molecules in solution, and isomerization of one or both Asp-92 residues deactivated one or both antigen-binding regions, respectively. In addition, isomerization of Asp-92 showed a decrease in in vitro potency as measured by a cell proliferation assay with a 32D cell line that expressed the full-length human EGFR. The data indicate that antibodies containing either one or two isomerized residues were not effective in inhibiting EGFR-mediated cell proliferation, and that two unmodified antigen binding regions were needed to achieve full efficacy. For comparison, the potency of an intact IgG1 antibody cetuximab against the same receptor was correlated with the bioactivity of its individual antigen-binding fragments. The intact IgG1 antibody with two antigen-binding fragments was also much more active in suppressing cell proliferation than the individual fragments, similar to the IgG2 results. These results indicated that avidity played a key role in the inhibition of cell proliferation by these antibodies against the human EGFR, suggesting that their mechanisms of action are similar.

Overview

Integrity signals

Registry

Crossref · 10.1021/bi7018223

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 46

  1. Carpenter G., 2000, Bioassays 22, 697−707.
  2. Wu D. G., 1990, Proc. Natl. Acad. Sci. U.S.A. 87
  3. Burgess A. W., 2003, Mol. Cell 12, 541−552.
  4. Franklin M. C., 2004, Cancer Cell 5, 317−328.
  5. Dawson J. P., 2005, Mol. Cell. Biol. 25, 7734−7742.
  6. Hynes N. E., 2005, Nat. Rev. Cancer, 5
  7. Herbst R. S., 2002, Cancer 94, 1593−1611.
  8. Kawamoto T., 1983, Proc. Natl. Acad. Sci. U.S.A. 80
  9. Foon K. A., 2004, Int. J. Radiat. Oncol. Biol. Phys., 58
  10. Scott A. M., 2007, Proc. Natl. Acad. Sci. U.S.A. 104
  11. Adams G. P., 2006, Clin. Cancer Res. 12, 1599−1605.
  12. Gan H. K., 2007, J. Biol. Chem., 282
  13. Geiger T., 1987, J. Biol. Chem., 262
  14. Oliyai C., 1994, Pharm. Res. 11, 751−758.
  15. Johnson B. A., 1989, J. Biol. Chem., 264
  16. Potter S. M., 1993, III, and IV, Protein Sci. 2, 1648−1663.
  17. Lam X. M., 1997, J. Pharm. Sci., 86
  18. Stephenson R. C., 1989, J. Biol. Chem., 264
  19. Xiao G., 2007, Anal. Chem. 79, 2714−2721.
  20. Cacia J., 1996, Biochemistry 35
  21. Harris R. J., 2001, J. Chromatogr. B: Biomed. Sci. Appl. 752, 233−245.
  22. Wakankar A. A., 2007, J. Pept. Sci., 96
  23. Wakankar A. A., 2007, Biochemistry 46, 1534−1544.
  24. Di Donato A., 1993, J. Biol. Chem., 268
  25. Zhang W., 2002, Pharm. Res. 19, 1223−1231.
  26. Chelius D., 2005, Anal. Chem. 77, 6004−6011.
  27. Qian R. L., 1997, J. Chromatogr. A, 787
  28. Santora L. C., 2001, Anal. Biochem. 299, 119−129.
  29. Yang X. D., 1999, Cancer Res. 59, 1236−1243.
  30. Jakobovits A., 2007, Nat. Biotechnol. 25, 1134−1143.
  31. Goldstein N. I., 1995, Clin. Cancer Res. 1, 1311−1318.
  32. Li S., 2005, Cancer Cell 7, 301−311.
  33. Harding J., 2005, Drugs Today 41, 107−127.
  34. Zhang Z., 2004, Anal. Chem. 76, 3908−3922.
  35. Gadgil H. S., 2006, Anal. Biochem. 355, 165−174.
  36. Korman A. J., 1987, Proc. Natl. Acad. Sci. U.S.A. 84
  37. Ritz-Timme S., 2002, Ageing Res. Rev., 1, 59
  38. Chu G. C., 2007, J. Pharm. Res., 24
  39. Pierce J. H., 1988, Science 239, 628−631.
  40. Yang S., 2006, Cancer Res. 66, 6990−6997.
  41. Chen Y. R., 2006, Oncogene 25, 1205−1215.
  42. Fan Z., 1993, Cancer Res. 53, 4322−4328.
  43. Fan Z., 1994, J. Biol. Chem., 269
  44. Honegger A., 2001, J. Mol. Biol., 309
  45. Friedman L. M., 2005, Proc. Natl. Acad. Sci. U.S.A. 102
  46. Foltz, I. N., King, C. T., and Liang, M. (2007) Panitumumab induces internalization of the epidermal growth factor receptor [abstract B43 plus poster], 17th American Association for Cancer Research−National Cancer Institute−European Organization for the Research and Treatment of Cancer (AACR-NCI Disclosure EORTC) International Conference on Molecular Targets and Cancer Therapeutics; Nov 14−18, 2005, Philadelphia, PA; p 136.

Cited by

Items 101–118 of 118

Metadata

Authors
Rehder, D. S., Chelius, D., McAuley, A., Dillon, T. M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D. N., Matsumura, M., & Bondarenko, P. V.
Affiliations
Amgen (United States) (US)
Corresponding author
  • Rehder, Douglas S.
  • Bondarenko, Pavel V.
Venue
Biochemistry
Published
2008-01-31
Volume
47
Issue
8
Pages
2518-2530
ISSN
  • 0006-2960 (ISSN-L)
  • 1520-4995
OpenAlex
W2018172073
Cited by
110
References
24
Citations by year
2025: 1 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 12 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 10 · 2013: 7 · 2012: 4
FWCI
5.12
Type
journal article
Language
en
Open access
closed
Locations
  • Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords
anti-EGFR monoclonal antibody, panitumumab, cetuximab, antibody avidity, antigen-binding region, in vitro aging
MeSH terms
Panitumumab, Alkylation, Amino Acid Sequence, Antibodies, Monoclonal, Antibody Affinity, Antibody Formation, Aspartic Acid, Cells, Cultured, Chromatography, High Pressure Liquid, Humans, Immunoglobulin gamma-Chains, Immunoglobulin Light Chains, Isomerism, Models, Molecular, Molecular Sequence Data, Oxidation-Reduction, Protein Processing, Post-Translational, Structure-Activity Relationship, Transferases, Protein Isoforms, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.